<DOC>
	<DOCNO>NCT00242307</DOCNO>
	<brief_summary>The aim study investigate effect roflumilast ( APTA-2217 ) lung function patient asthma . Roflumilast administer orally daily . The study duration consist baseline period ( 2 4 week ) treatment period ( 24 week ) . The study provide data safety , tolerability , effectiveness roflumilast .</brief_summary>
	<brief_title>Efficacy Safety Roflumilast Japanese Patients With Bronchial Asthma ( 20 70 ) ( APTA-2217-05 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Main inclusion criterion : Adult patient bronchial asthma meeting Guideline Prevention Control Asthma 2003 ( JGL 1998 , revise 2nd edition ) No change asthma treatment last 4 week prior registration Nonsmokers exsmokers 12 month % FEV1 range 60 80 % Main exclusion criterion : Patients poorly control asthma Inhalation therapy exceed low dose 4 week prior registration Concurrent respiratory disease COPD consider affect efficacy evaluation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Roflumilast</keyword>
	<keyword>phosphodiesterase 4 inhibitor</keyword>
</DOC>